Payment overview · 2025
General Payments
$420.05
25 reported records · 11 companies
Healthcare provider profile · identity verified
Daniel W Hyler, MD
Allopathic & Osteopathic Physicians|Family Medicine · FLORENCE, SC · NPI 1851365498
Verified facts
What the public records show
CMS Open Payments records show Daniel W Hyler, MD received $420.05 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 46.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $197.13 | 46.9% | 13 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $44.40 | 10.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.02 | 7.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.02 | 5.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.88 | 5.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.41 | 4.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.99 | 4.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.98 | 4.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.64 | 3.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.91 | 3.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.67 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $420.05 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $114.07 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.66 | 3 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $44.40 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $38.57 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.02 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $33.02 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.40 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 350 | 94 |
| Alprazolam | Alprazolam | 313 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 305 | 82 |
| Pravastatin Sodium | Pravastatin Sodium | 285 | 74 |
| Furosemide | Furosemide | 263 | 78 |
| Omeprazole | Omeprazole | 243 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 229 | 56 |
| Montelukast Sodium | Montelukast Sodium | 204 | 43 |
| Prednisone | Prednisone | 204 | 65 |
| Gabapentin | Gabapentin | 188 | 52 |
| Metformin Hcl | Metformin Hcl | 186 | 47 |
| Lisinopril | Lisinopril | 170 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 160 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 129 | 27 |
| Meloxicam | Meloxicam | 127 | 30 |
| Glipizide | Glipizide | 126 | 32 |
| Donepezil Hcl | Donepezil Hcl | 123 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 30 |
| Ibandronate Sodium | Ibandronate Sodium | 114 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 32 |
| Simvastatin | Simvastatin | 110 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 31 |
| Potassium Chloride | Potassium Chloride | 108 | 24 |
| Carvedilol | Carvedilol | 107 | 27 |
| Losartan Potassium | Losartan Potassium | 107 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 31 |
| Trazodone Hcl | Trazodone Hcl | 105 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 47 |
| Eliquis | Apixaban | 98 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 94 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 24 |
| Tramadol Hcl | Tramadol Hcl | 78 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 18 |
| Allopurinol | Allopurinol | 75 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 68 | 16 |
| Clonazepam | Clonazepam | 66 | suppressed |
| Ezetimibe | Ezetimibe | 65 | 17 |
| Sucralfate | Sucralfate | 65 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 61 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 15 |
| Diazepam | Diazepam | 53 | 12 |
| Ibuprofen | Ibuprofen | 53 | 25 |
| Lorazepam | Lorazepam | 53 | 13 |
| Pregabalin | Pregabalin | 53 | 11 |
| Meclizine Hcl | Meclizine Hcl | 50 | 19 |
| Levofloxacin | Levofloxacin | 49 | 29 |
| Ozempic | Semaglutide | 49 | 12 |
| Spironolactone | Spironolactone | 49 | 16 |
| Sertraline Hcl | Sertraline Hcl | 48 | 15 |
| Mirtazapine | Mirtazapine | 46 | 16 |
| Naproxen | Naproxen | 44 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Fluconazole | Fluconazole | 34 | 17 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 21 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 18 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Clarithromycin | Clarithromycin | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $420.05 · 25 records | ABBVIE INC. | ACCRUFER, APRETUDE, AREXVY, Auvelity, CREON, Cologuard Collection Kit, FANAPT, HETLIOZ, Korlym, LINZESS, MOUNJARO, Ozempic, REXULTI, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error